A model of post-traumatic stress disorder based on endocannabinoid deficiency: potential implications for therapy
Suggested citation:
Kemeron K, Adile T, Akhmed AG. [A model of post-traumatic stress disorder based on endocannabinoid deficiency: potential implications for therapy]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2021;(2):54-61. Russian
This scientific review, aimed at analyzing the endocannabinoid system, the neurobiological effects of cannabinoids, and the endocannabinoid deficiency model of post-traumatic stress disorder (PTSD), examines the evidence base indicating the possibility of using cannabinoids in the treatment of PTSD. Particular attention is given to studies on the use of nabilone, a synthetic cannabinoid 1 receptor agonist (C1), for the treatment of PTSD related insomnia and nightmares, including in those with multiple psychiatric co-morbidities, substance use disorder and chronic pain. Suggestions are given for future lines of research to further elucidate the possible role for agents acting on the endocannabinoid system in the treatment of PTSD.
Keywords post-traumatic stress disorder (PTSD); cannabinoids; endocannabinoid system; nabilone
1. Romero-Sandoval EA, Kolano AL, Alvarado-Vázquez PA. Cannabis and Cannabinoids for Chronic Pain. Curr Rheumatol Rep. 2017;19(11):67. DOI: https://doi.org/10.1007/s11926-017-0693-1 2. Grotenhermen F, Muller-Vahl K. The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl Int. 2012;109(29–30):495–501. DOI: https://doi.org/10.3238/arztebl.2012.0495 3. Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol. 2006;105(1–2):1–25. DOI: https://doi.org/10.1016/j.jep.2006.02.001 4. Zhang Y, Ren R, Sanford LD, et al. The effects of prazosin on sleep disturbances in post-traumatic stress disorder: a systematic review and meta-analysis. Sleep Med. 2020;67:225–31. DOI: https://doi.org/10.1016/j.sleep.2019.06.010 5. VA/DoD Clinical PracticeGuideline for theManagement of Posttraumatic StressDisorder andAcute StressDisorder. Department of Veterans Affairs, Department of Defence, 2017, version 3.0. URL: https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal012418.pdf (accessed on: 10.04.2021). 6. Kessler RC, Sonnega A, Bromet E, et al. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1995;52(12):1048–60. DOI: https://doi.org/10.1001/archpsyc.1995.03950240066012 7. Pietrzak RH, Goldstein RB, Southwick SM, Grant BF. Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. J Anxiety Disord. 2011;25(3):456–65. DOI: https://doi.org/10.1016/j.janxdis.2010.11.01 8. Bilevicius E, Sommer JL, Asmundson GJG, El-Gabalawy R. Associations of PTSD, chronic pain, and their comorbidity on cannabis use disorder: Results from an American nationally representative study. Depress Anxiety. 2019;36(11):1036–46. DOI: https://doi.org/10.1002/da.22947 9. Meng H, Johnston B, Englesakis M, et al. Selective Cannabinoids for Chronic Neuropathic Pain: A Systematic Review and Meta-analysis. Anesth Analg. 2017;125(5):1638–52. DOI: https://doi.org/10.1213/ANE.0000000000002110 10. Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain: a systematic review of randomized trials. Br J Clin Pharmacol. 2011;72(5):735–44. DOI: https://doi.org/10.1111/j.1365-2125.2011.03970.x 11. Papaseit E, Pérez-Mañá C, Pérez-Acevedo AP, et al. Cannabinoids: from pot to lab. Int J Med Sci. 2018;15(12):1286–95. DOI: https://doi.org/10.7150/ijms.27087 12. Lu HC, Mackie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016;79(7):516–25. DOI: https://doi.org/10.1016/j.biopsych.2015.07.028 13. Svizenska I, Dubovy P, Sulcova A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures – A short review. Pharmacol Bichem Be. 2008;90(4):501–11. DOI: https://doi.org/10.1016/j.pbb.2008.05.010 14. Hill M, Campolongo P, Yehuda R, et al. Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder. Neuropsychopharmacol. 2018;43(1):80–102. DOI: https://doi.org/10.1038/npp.2017.162 15. Jiang W, Zhang Y, Xiao L, et al. Cannabinoids promote embryonic and adult hippocampal neurogenesis and produce anxiolytic and antidepressant-like effect. J Clin Invest. 2005;115(11):3104–16. DOI: https://doi.org/10.1172/JCI.7.25509 16. Bremner JD, Randall P, Scott TM, et al. MRI-based measurements of hippocampal volume in combat-related post-traumatic stress disorder. Am J Psychiatry. 1995;152(7):973–81. DOI: https://doi.org/10.1176/ajp.152.973 17. Gilbertson MW, Shenton ME, Ciszewski A, et al. Smaller hippocampal volume predicts pathologic vulnerability to psychological trauma. Nat Neurosci. 2002;5(11):1242–7. DOI: https://doi.org/10.1038/nn.9588 18. Gurvits TV, Shenton ME, Hokama H, et al. Magnetic resonance imaging study of hippocampal volume in chronic, combat-related post-traumatic stress disorder. Biol Psychiatry. 1996;40(11):1091–9. DOI: https://doi.org/10.1016/S0006-3223(96)00229-6 19. Hill MN, Bierer LM, Makotkine I, et al. Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the World Trade Center attacks. Psychoneuroendocrinology. 2013;38(12):2952–61. DOI: https://doi.org/10.1016/j.psynuen.2013.08.004 20. Shannon S, Lewis N, Lee H, Hughes S. Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm J. 2019;23:18–41. DOI: https://doi.org/10.7812/TPP/18-041 21. Fabre LF, McLendon D. The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety. J Clin Pharmacol. 1981;21(S1):377S–82S. DOI: https://doi.org/10.1002/j.1552-4604.1981.tb02617.x 22. Babson KA, Sottile J, Morabito D. Cannabis, Cannabinoids, and Sleep: a Review of the Literature. Curr Psychiatry Rep. 2017;19(4):23. DOI: https://doi.org/10.1007/s11920-017-0775-9 23. Carlini EA, Cunha JM. Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol. 1981;21(S1):417S–27S. DOI: https://doi.org/10.1002/j.1552-4604.1981.tb02622.x 24. Nabilone for Chronic Pain Management: A Review of Clinical Effectiveness, Safety, and Guidelines, Rapid Response Report: Summary with Critical Appraisal, Canadian Agency for Drugs and Technologies in Health. November 2011. URL: https://www.cadth.ca/media/pdf/htis/oct-2011/RC0306-000%20Nabilone%20for%20chronic%20pain.pdf (accessed on: 10.04.2021). 25. Ware MA, St Armand E. The abuse potential of the synthetic cannabinoid nabilone. Addiction. 2010;105(3):494–503. DOI: https://doi.org/10.1002/j.1552-4604.1981.tb02622.x 26. Lile JA, Kelly TH, Hays LR. Substitution profile of the cannabinoid agonist nabilone in human subjects discriminating delta-9-tertrahydrocannabinol. Clin Neuropharmacol. 2012;33(5):235–42. DOI: https://doi.org/10.1097/wnf.0b013e3181e77428 27. Fraser GA. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther. 2009;15(1):84–8. DOI: https://doi.org/10.1111/j.1755-5949.2008.00071.x 28. Jetly R, Heber A, Fraser G, Boisvert D. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology. 2015;51:585–8. DOI: https://doi.org/10.1016/j.psyneuen.2014.11.002 29. Meakin C, Fraser G, Boivert D, Miller C. Use of a synthetic cannabinoid (nabilone) in the ongoing management of posttraumatic stress disorder nightmares in the Canadian Armed Forces. JMVFH. 2020;6(2):3–8. DOI: https://doi.org/10.3138/jmvfh-2019-0028 30. Cameron C, Watson D, Robinson J. Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation. J Clin Psychopharmacol. 2014;34(5):559–64. DOI: https://doi.org/10.1097/jcp.0000000000000180
DOI: http://dx.doi.org/10.47877/1560-957Х-2021-10206
Article Metrics
Metrics powered by PLOS ALM